TY - JOUR T1 - Anti-IL-5 mepolizumab对严重哮喘中残余血液嗜酸性粒细胞影响最小JF -欧洲呼吸杂志JO - Eur Respir J DO - 10.1183/13993003.00935-2021 SP - 2100935 AU - Van Hulst, Glenn AU - Jorssen, Joseph AU - Jacobs, Nathalie AU - Henket, Monique AU - Louis, Renaud AU - Schleich, Florence AU - Bureau, Fabrice AU - Desmet，Christophe J. Y1 - 201/01/01 UR - //www.qdcxjkg.com/content/early/2021/07/29/13993003.00935-2021.abstract N2 -对抗细胞因子白介素(IL)-5的中和抗体已广泛用于控制严重嗜酸性粒细胞性哮喘。值得注意的是，接受中和抗il - 5生物治疗的患者保留了非常稳定的残余嗜酸性粒细胞种群。这些残余嗜酸性粒细胞是否具有特定的生物活性尚未被研究，但对于预测IL5中和对患者的潜在长期影响很重要。为了解决IL5缺失对残余嗜酸性粒细胞的影响，我们使用比较rna测序方法，比较了IL5缺失或IL5填充的人或鼠宿主中产生的嗜酸性粒细胞的基因表达程序，在体内稳定状态下，在体外刺激后与IL33中的嗜酸性粒细胞激活警报。我们比较了接受抗il - 5 mepolizumab治疗的严重过敏性嗜酸性哮喘患者的血液嗜酸性粒细胞与健康对照组和接受抗ige omalizumab治疗的哮喘患者的血液嗜酸性粒细胞。我们对IL5基因缺乏或不缺乏的小鼠骨髓嗜酸性粒细胞进行了类似的比较。我们报道，在mepolizumab治疗的患者或IL5缺陷小鼠的稳态残留嗜酸性粒细胞中，IL5可用性的限制没有引起任何可检测到的转录反应，并且仅影响其对IL33反应的少数基因。总之，这些结果支持了这样一种观点，即用IL5中和抗体治疗可以避免大量循环中残留的嗜酸性粒细胞，这些细胞与健康人的嗜酸性粒细胞非常相似。这篇手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以其可接受的形式在这里发布。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Glenn Van Hulst has nothing to disclose.Conflict of interest: J. Jorssen reports PhD student scholarship from Fonds de la Recherche scientifique (FRS)-FNRS (Belgium).Conflict of interest: N. Jacobs reports consulting fees and lecture fees from GSK, outside the submitted work.Conflict of interest: Monique Henket has nothing to disclose.Conflict of interest: L. Renaud reports grants from GSK, AZ, Novartis, Chiesi and Teva; royalties from patent AU2016328384, CA2997506, EP 3337393, US2020345266; consulting fees and lecture payments from GSK, AZ, Novartis, Sanofi and Chiesi, outside the submitted work.Conflict of interest: F. Schleich reports grants from GSK, Astrazeneca, Teva, Chiesi and Novartis; consulting fees from GSK, Astrazeneca, Amgen, Chiesi and Novartis; lecture payments from GSK, Astrazeneca, Teva, Chiesi and Novartis, outside the submitted work.Conflict of interest: Fabrice Bureau has nothing to disclose.Conflict of interest: C. Desmet reports salary from Fonds de la Reherche Scientifique – FNRS (Belgium), during the submitted work; consulting fees in Advisory Board on eosinophil research from AstraZeneca; lecture fees for presentation at several scientific symposia in Europe on our research on eosinophils from GSK, outside the submitted work. ER -